Loading peptide…
PeptideChat is for educational and research purposes only. Nothing on this site constitutes medical advice. Peptides are sold as research chemicals only and are not intended for human use. These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. PeptideChat is an independent educational resource — not a pharmacy, compounding, or 503A/503B outsourcing facility — and does not sell products or provide medical advice.
Also known as: Mazdutide, GLP-1.3, IBI362
Mazdutide (IBI362) is an investigational dual agonist of the GLP-1 and glucagon receptors based on the oxyntomodulin scaffold. It is being studied for weight loss and glycemic control.
Sign in to rate this peptide.
Mazdutide is a long-acting analog of oxyntomodulin that simultaneously activates the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR). GLP-1R agonism enhances glucose-dependent insulin secretion, slows gastric emptying, and promotes satiety through hypothalamic appetite circuits, while glucagon receptor agonism increases energy expenditure and hepatic lipid utilization. The combined incretin-plus-glucagon signaling is intended to drive greater weight loss and metabolic improvement than GLP-1 activity alone, with fatty-acid acylation extending its half-life for once-weekly dosing.